跳到正文
原文
Medical Xpress·· 2026-10-14AI 评分47

Cell Reports Medicine:融合环工程化Zika疫苗在非人灵长类模型中解除保护与ADE的耦合

Vaccine redesign may separate Zika protection from risk of worsening dengue

AI 导读

一项发表在Cell Reports Medicine上的研究(10月7日)报道了一种针对Zika病毒的融合环工程化mRNA疫苗。在非人灵长类(食蟹猴)模型中,该疫苗激发的高特异性B细胞免疫反应成功阻断了病毒进入的多个阶段,同时排除了抗体依赖性增强(ADE)风险,为临床评价奠定了基础。

正文
Researchers make progress on Zika vaccine using nonhuman primate model
The fusion-loop-engineered Zika vaccine achieves protection in macaques and abolishes ADE risk. Credit: Dai Lianpan's group

A fusion-loop-engineered vaccine against the Zika virus (ZIKV) has shown promise in a nonhuman primate model. The research was reported in Cell Reports Medicine on Oct. 7.

This type of vaccine modifies a region of the viral envelope protein known as the fusion loop to stimulate protective antibodies while reducing the risk of antibody-dependent enhancement (ADE), in which antibodies can worsen infection rather than prevent it. ADE is a major concern in flavivirus vaccine development. These findings lay a foundation for the further clinical evaluation of Zika virus vaccines.

The study was led by professors Dai Lianpan and George F. Gao from the Institute of Microbiology of the Chinese Academy of Sciences (CAS) and Dr. Lu Shuaiyao from the Institute of Medical Biology of the Chinese Academy of Medical Sciences.

ZIKV is a mosquito-borne pathogen that can cause neonatal microcephaly. Currently, there are no licensed vaccines available, and prior ZIKV immunity may increase the risk of ADE, which can exacerbate dengue virus (DENV) infection—representing a major hurdle for vaccine development.

Previously, the research team designed the fusion-loop-engineered immunogen MutB, which achieved maternal–fetal protection while abolishing ADE in murine models. However, given the substantial differences between the murine and human immune systems, it was unclear whether fusion-loop-engineered vaccines could elicit the desired immune response in humans.

To investigate the immune response elicited by the vaccine, the researchers analyzed vaccine-induced B cells and found that more than 97% were ZIKV-specific. These cells were dominated by a convergent population using a germline ortholog of human IGHV5-10-1, a gene preferentially recruited during natural ZIKV infection in humans.

Antibodies derived from this population are highly potent and, mechanistically, achieve multistage viral entry blockade. Cryo-electron microscopy analysis revealed that these antibodies target a distinct, vulnerable hotspot on ZIKV. ZIKV specificity is dictated by the epitope residues D67–M68–A69, whereas a homologous DENV N67-linked glycan imposes steric shielding to preclude cross-reactivity.

These findings demonstrate that fusion-loop engineering uncouples protective immunity from ADE for safer human flavivirus vaccines.

Publication details

Chenxi Yang et al., Fusion-loop-engineered Zika mRNA vaccine elicits convergent B cell immunodominance to uncouple protection from ADE in macaques, Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.103091

Journal information: Cell Reports Medicine

Key medical concepts

Zika Virus

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Vaccine redesign may separate Zika protection from risk of worsening dengue (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-vaccine-redesign-zika-worsening-dengue.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com